David Sher, MD, MPH, Professor, Chief of Head and Neck Radiation Oncology, and Vice Chair and Medical Director for Clinical Operations and Quality at UT Southwestern Medical Center, shared on X:
“I now routinely perform PET-CT simulation for high-risk postop H&N cases and not uncommonly find residual (or progressive) FDG-avid disease.
It makes me question whether the postop RT literature on intensification needs to be re-examined. How much is the benefit of chemotherapy, or prompt RT start, or even nivolumab, related to its efficacy in managing actual gross disease versus microscopic residual.”
You can also read: Rebuilding the Enemy: How 3D Bioprinting Is Changing Research Into Head and Neck Cancer
